In agreement with several lines of evidence involving the purinergic adenosine A2a receptor in immune evasion of tumor cells [69–71], we find that regadenoson, an A2a receptor agonist, shares phenotypic features with heart neoplasms. This evidence concerns the gene ADORA2A and heart neoplasm.